Application of Saccharomyces boulardii in combination with sulfasalazine in ulcerative colitis patients demonstrates significant effectiveness  

作　　者：Chun-Chun Yang Sui Zhang Rui Zhang Ya-Nan Zhao Da-Wei Yang Ming-Yue Yang Li-Jing Huang 

机构地区：[1]Department of Gastroenterology,The First Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei Province,China [2]Department of Hepatic,The First Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei Province,China [3]Department of Gastroenterology Center,The First Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei Province,China [4]Department of Rheumatology and Immunology,The First Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2025年第2期173-182,共10页世界胃肠外科杂志(英文)

摘　　要：BACKGROUND Ulcerative colitis(UC)is a complex inflammatory bowel disease,and its etiology and pathogenesis remain incompletely elucidated.AIM To analyze the effects of Saccharomyces boulardii in combination with sulfasalazine on intestinal microbiota and intestinal barrier function in patients with UC.METHODS A retrospective analysis of clinical data from 127 UC patients admitted to our hospital between January 2021 and January 2023 was conducted.All patients met complete inclusion and exclusion criteria.Based on the treatment interventions received,they were divided into a control group(n=63)and an observation group(n=64).Both groups of patients received routine treatment upon admission.The control group received sulfasalazine in addition to routine interventions,while the observation group received a combination of Saccharomyces boulardii on the basis of the control group’s treatment.The clinical efficacy,improvement in symptoms,modified Baron endoscopic scores,quality of life“inflammatory bowel disease questionnaire(IBDQ)”,levels of intestinal microbial indicators(such as Lactobacillus,Bifidobacterium,Enterococcus,and Escherichia coli),intestinal mucosal barrier function indicators[diamine oxidase(DAO),lipopolysaccharide(LPS),D-lactic acid(D-LA)],and adverse reaction occurrences were compared between the two groups.RESULTS(1)Clinical efficacy:The total effective rate in the control group was 79.37%,while in the observation group,it was 93.75%,significantly higher than that of the control group(P<0.05);(2)Improvement in symptoms:The observation group showed significantly lower relief time for abdominal pain,diarrhea,rectal bleeding,fever symptoms,and mucosal healing time compared to the control group(P<0.05);(3)Baron endoscopic scores and IBDQ scores:Before treatment,there was no significant difference in Baron endoscopic scores and IBDQ scores between the two groups(P>0.05).However,after treatment,the observation group showed significantly lower Baron endoscopic scores and higher IBDQ scores compared to

关 键 词：Saccharomyces boulardii SULFASALAZINE Ulcerative colitis Intestinal microbiota Intestinal barrier function IMPACT 

分 类 号：R574.62[医药卫生—消化系统]